In the view of previous studies, the development of a selective GR ligand with few side-effects has become a new development direction and research strategy for the treatment of chronic inflammation, which may be applied to the remission of type 2 diabetes mellitus (11). The gene discussed is NR3C1; the disease is diabetes mellitus.